Quest Diagnostics Inc

DGXNYSE · USD
256.35USD0.00 (-2.24%)
779

Quest Diagnostics Inc (DGX) Covered Calls

Quest Diagnostics Inc trades in the Diagnostics & Research industry with an IV Rank of 73.81%, high versus the past year. DGX's highest covered call setup is the $280.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 6.78% out of the money with 4 days to expiration, a 6.80% return until expiration, and a 620.84% theoretical annualized return. Across the setups shown, annualized returns run from 57.94% to 620.84% at strikes between $270.00 and $350.00, with 4 to 186 days to expiration, as of Nov 16, 2026.

Read more

Running DGX covered calls helps you generate income from Quest Diagnostics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best DGX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If DGX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling DGX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given DGX covered call is worth writing.

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals.

2026-11-204280.006.780.052.701784.006.80620.84-0.02+0.161302.65
2026-11-204270.002.970.202.35799.003.05278.05-0.08+0.237222.15
2026-12-1832290.0010.600.202.302799.0010.67121.76-0.08+0.1252.10
2027-02-1995330.0025.850.053.106784.0025.8799.40-0.02+0.0923.05
2026-12-1832280.006.781.653.801944.007.4184.56-0.63+0.23932.15
2027-02-1995310.0018.230.304.004809.0018.3470.47-0.11+0.13143.70
2027-01-1560290.0010.600.904.302869.0010.9466.56-0.34+0.1903.40
2027-05-21186350.0033.480.053.608784.0033.5065.74-0.02+0.0903.55
2027-05-21186340.0029.670.504.007829.0029.8658.59-0.19+0.1103.50
2027-02-1995300.0014.411.754.803954.0015.0857.94-0.67+0.196603.05

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDiagnostics & Research
  • SectorHealthcare
  • IV Rank73.81% High
  • Market cap (M$)28,203
  • 52 weeks high-2.60%
  • 52 weeks low49.75%
  • Analyst recommendationBuy
    2.06
  • Target price$258.29
    0.76% above the current stock price
  • Dividend—
  • Payout ratio36.60%
  • Earnings date2027-02-09
  • P/E25.52
  • Future P/E21.39
  • EPS (ttm)10.04
  • EPS growth next 5 years9.85%

As of Nov 17, 2026